About Us

image 4

Dr. Liang Ouyang’s team been studying molecular mechanisms of apoptosis and autophagy, identifying novel protein targets and designing novel small molecule compound and protein& peptide candidate drugs in cancer therapy.

State/National Key Laboratory of Biotherapy (SKLB) was established by the Ministry of Sciences and Technology in China in 2005, and became one of the National Research and Development (R&D) Platforms for Novel Drugs founded by the Ministries of Sciences and Technology as well as Public Health in September 2008. It is also supported by National Collaborative Innovation Program and became the National Collaborative Innovation Center for Biotherapy in April 2013. The Platform is located in the High Tech Zone of Chengdu and the Medical Campus of Sichuan University. The overall space is nearly 70,000 square meters and is still under intensive growth and construction. SKLB also has rich clinical resources of West China Hospital, which has 4,300 beds.

Dr. Liang Ouyang

image 5

Liang Ouyang was born in 1983 in Chengdu, China. He obtained his Ph.D. in 2010 from West China School of Pharmacy, Sichuan University. From August 2010 to August 2012, he worked with Prof. Yu-quan Wei as a postdoctoral associate at the State key lab of biotherapy, Sichuan university. Then he joined the faculty of State key lab of biotherapy as an assistant professor in 2013. His research has been focused on the Diversity-oriented synthesis of bioactive natural products and Medicinal chemistry.

As a major participant, Dr. Ouyang completed a novel design, synthesis and biological activity evaluation of bone-targeted drug carriers acidic oligopeptide for bone disease. He also participated in developing small molecule apoptosis- and/or autophagy-modulating drugs targeting ERK-1, AMPK/ZIPK, eEF2K, ULK-1 and SIRT-3 using diversity-oriented synthesis.